POTOMAC FALLS, VA, June 21, 2013
Metabiomics, an early stage microbiome diagnostics company, will be presenting an investment opportunity next week at OneMedForumNY in New York. The 4th annual OneMedForumNY investor conference will be held on June 26-27 at the Metropolitan Club in New York City; the theme of which being the future of growth company financing, with a look at private alternative markets and the reemergence of the IPO.
Metabiomics, a start-up poised for high growth, is developing a non-invasive screening test for colon polyps and colorectal cancer that is being tailored to increase colorectal cancer screening compliance and reduce healthcare costs, morbidity, and mortality by detecting adenomas earlier and better optimizing the usage of expensive and invasive colonoscopy procedures. Metabiomics has a unique approach to polyp detection that hinges on an advanced interrogation of the human gut microbiome.
Metabiomics is raising funding to support concurrent clinical studies in the United States and China. In the United States, the study will be supported by a network of clinical collaborators and private investors and leveraged by alternative and non-dilutive funding. In China, Metabiomics recently announced a partnership with Kindstar Global, the leading specialty clinical testing laboratory in China, who will support and fund the Chinese clinical validation effort. Kindstar currently services more than 3,300 hospitals across China from three centralized laboratories in Beijing, Shanghai and Wuhan, making the collaboration a promising strategy for rapid commercialization.
Metabiomics Vice President of Business Development, Greg Kuehn, will present a commercialization strategy at 10:20 am on July 27. President and CEO, Dr. Thomas Kuehn will also be in attendance and available for partnering meetings.
About Metabiomics
Metabiomics Corporation is an early-stage, diagnostics company that is developing non-invasive screening tests for gastrointestinal and autoimmune diseases based on human microbiome biomarkers. The company has developed/licensed patented/patent-pending technology that integrates advances in microbial ecology, next-generation DNA sequencing, and computational systems biology. These innovations were developed over the past 10 years in collaboration with Dr. Patrick Gillevet, Vice President and Chief Scientific Officer of Metabiomics, at the Microbiome Analysis Center at George Mason University and many other clinical research partners at leading academic medical centers in the US and Canada. Metabiomics was formed in 2011 as a wholly owned subsidiary of BioSpherex LLC to focus on molecular diagnostic application of human microbiome research in translational medicine.
For More Information Visit: http://metabiomics.com
Metabiomics Safe Harbor Statement: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential results and future outcomes our clinical research and business plan; ability to discover biomarkers and diagnostic tests; our beliefs regarding the need for and value of molecular diagnostics; and the focus and attributes of the company’s product pipeline, including the ability of the company’s tests to impact clinical practice. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the results of clinical and developmental studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests and the timing thereof; unanticipated costs or delays in research and development efforts; the applicability of initial next generation sequencing studies to future results; the risk that we may not obtain or maintain reimbursement for diagnostic tests we may develop, both domestically and abroad; our ability to compete against third parties; the risks and uncertainties associated with the regulation of our tests by the FDA and other agencies abroad; and the other risks set forth in the company’s business plans and presentations. These forward- looking statements speak only as of the date hereof. Metabiomics disclaims any obligation to update these forward-looking statements.